• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Botulinum toxin type A for the treatment of dyssynergic defaecation in adults: a systematic review.

作者信息

Chaichanavichkij P, Vollebregt P F, Scott S M, Knowles C H

机构信息

National Bowel Research Centre and GI Physiology Unit (Colorectal Services), Centre of Neuroscience, Surgery and Trauma, Blizard Institute, Queen Mary University of London, London, UK.

出版信息

Colorectal Dis. 2020 Dec;22(12):1832-1841. doi: 10.1111/codi.15120. Epub 2020 Jun 11.

DOI:10.1111/codi.15120
PMID:32403161
Abstract

AIM

Dyssynergic defaecation (DD) is characterized by inappropriate coordination of the pelvic floor muscles during defaecation, resulting in impaired stool expulsion. The mainstay of treatment is biofeedback and alternative therapies are limited in those who do not respond. This systematic review evaluated botulinum toxin type A injection (BTXA) as a treatment option for dyssynergia.

METHODS

PubMed, Embase and Cochrane Central Register of Controlled Trials were searched for studies evaluating adult patients with DD treated with BTXA injection into the puborectalis and/or external anal sphincter. All study designs, except case reports, were included in the review with no language restriction. Studies limited to patients with specific neurological diagnoses or with a follow-up period under 1 month were excluded. Study selection, assessment and data extraction were performed by two reviewers and results were synthesized narratively.

RESULTS

Eleven studies (three randomized control trials) involving 248 participants were included. All studies used the transanal approach to deliver the injection, most commonly at the 3 and 9 o'clock positions using digital palpation for guidance. The most commonly used patient position was left lateral, and most studies did not use any anaesthesia. The dose of BTXA varied (Botox 12-100 units, Dysport 100-500 units), and outcomes measured were heterogeneous (global rating ± up to five investigations). Symptomatic improvement varied between 29.2% and 100% and adverse effects occurred in 0% to 70%.

CONCLUSION

The evidence to support using BTXA for DD is poor and only covers a transanal approach. Future studies should redress these limitations: heterogeneity of design, dose and outcome measures.

摘要

相似文献

1
Botulinum toxin type A for the treatment of dyssynergic defaecation in adults: a systematic review.
Colorectal Dis. 2020 Dec;22(12):1832-1841. doi: 10.1111/codi.15120. Epub 2020 Jun 11.
2
Biofeedback for treatment of chronic idiopathic constipation in adults.生物反馈疗法治疗成人慢性特发性便秘
Cochrane Database Syst Rev. 2014 Mar 26;2014(3):CD008486. doi: 10.1002/14651858.CD008486.pub2.
3
Biofeedback training versus botox injection for the treatment of dyssynergic defaecation: A randomized controlled trial.
Colorectal Dis. 2025 May;27(5):e70109. doi: 10.1111/codi.70109.
4
Botulinum toxin for myofascial pain syndromes in adults.肉毒杆菌毒素用于成人肌筋膜疼痛综合征
Cochrane Database Syst Rev. 2014 Jul 25;2014(7):CD007533. doi: 10.1002/14651858.CD007533.pub3.
5
Treatments for intractable constipation in childhood.儿童难治性便秘的治疗方法。
Cochrane Database Syst Rev. 2024 Jun 19;6(6):CD014580. doi: 10.1002/14651858.CD014580.pub2.
6
Botulinum toxin for myofascial pain syndromes in adults.肉毒杆菌毒素用于成人肌筋膜疼痛综合征
Cochrane Database Syst Rev. 2012 Apr 18(4):CD007533. doi: 10.1002/14651858.CD007533.pub2.
7
A systematic review and meta-analysis of biofeedback therapy for dyssynergic defaecation in adults.一项关于生物反馈疗法治疗成人功能性排便障碍的系统评价和荟萃分析。
Tech Coloproctol. 2020 Sep;24(9):909-918. doi: 10.1007/s10151-020-02230-9. Epub 2020 May 5.
8
Surgical management of functional bladder outlet obstruction in adults with neurogenic bladder dysfunction.成年神经源性膀胱功能障碍患者功能性膀胱出口梗阻的外科治疗
Cochrane Database Syst Rev. 2014 May 24;2014(5):CD004927. doi: 10.1002/14651858.CD004927.pub4.
9
Review article: dyssynergic defaecation and biofeedback therapy in the pathophysiology and management of functional constipation.综述文章:排便协同失调与生物反馈疗法在功能性便秘的病理生理学及管理中的应用
Aliment Pharmacol Ther. 2017 Aug;46(4):410-423. doi: 10.1111/apt.14174. Epub 2017 Jun 29.
10
Botulinum toxin type B for cervical dystonia.用于治疗颈部肌张力障碍的B型肉毒毒素
Cochrane Database Syst Rev. 2005 Jan 25(1):CD004315. doi: 10.1002/14651858.CD004315.pub2.

引用本文的文献

1
Outlet type constipation in adult patients treated with type A botulinum toxin: a cohort study.A型肉毒杆菌毒素治疗成年患者出口型便秘的队列研究。
Int J Colorectal Dis. 2025 Jan 21;40(1):22. doi: 10.1007/s00384-024-04795-5.
2
State of the Art Bowel Management for Pediatric Colorectal Problems: Functional Constipation.小儿结直肠问题的最新肠道管理:功能性便秘
Children (Basel). 2023 Jun 19;10(6):1078. doi: 10.3390/children10061078.